These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34886801)

  • 21. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
    Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
    HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
    Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
    Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early-onset pancreatic cancer: a population-based study using the SEER registry.
    Ansari D; Althini C; Ohlsson H; Andersson R
    Langenbecks Arch Surg; 2019 Aug; 404(5):565-571. PubMed ID: 31377855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of second primary pancreatic cancer.
    Jo JH; Cho IR; Jung JH; Lee HS; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Park JY
    PLoS One; 2017; 12(6):e0179784. PubMed ID: 28650984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
    Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
    J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.
    Qian L; Yu S; Yin C; Zhu B; Chen Z; Meng Z; Wang P
    Pancreatology; 2019 Mar; 19(2):340-345. PubMed ID: 30685120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and mid-term outcomes of robotic versus laparoscopic distal pancreatosplenectomy for pancreatic ductal adenocarcinoma: A retrospective propensity score-matched study.
    Qu L; Zhiming Z; Xianglong T; Yuanxing G; Yong X; Rong L; Yee LW
    Int J Surg; 2018 Jul; 55():81-86. PubMed ID: 29802919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
    Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
    J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma.
    Gong Y; Fan Z; Luo G; Huang Q; Qian Y; Cheng H; Jin K; Ni Q; Yu X; Liu C
    Pancreatology; 2020 Jun; 20(4):716-721. PubMed ID: 32249060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
    van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
    Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
    Pancreas; 2019; 48(10):1360-1366. PubMed ID: 31688602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.
    Li D; Morris JS; Liu J; Hassan MM; Day RS; Bondy ML; Abbruzzese JL
    JAMA; 2009 Jun; 301(24):2553-62. PubMed ID: 19549972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
    Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival.
    El Jellas K; Hoem D; Hagen KG; Kalvenes MB; Aziz S; Steine SJ; Immervoll H; Johansson S; Molven A
    Cancer Med; 2017 Jul; 6(7):1531-1540. PubMed ID: 28556564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.